2001 OPEN FORUM Abstracts
The ClinicalEfficacy of Using the AeroEclipse® Breath Actuated Nebulizer (BAN)in Pulmonary Lab Testing and Implications for General Use.
YM Christensen, RRT,CPFT, CJ Flanigan,RRT, SA Ravenscraft, M.D.,Park Nicollet Clinic, St. Louis Park, MN
Purpose: To compare theclinical efficacy and delivery time of nebulization of beta agonist bronchodilatorwith the use of the AeroEclipse® Breath Actuated Nebulizer (BAN) (Monaghan MedicalCorp.) as compared to the Airlife Misty-Neb Nebulizer (SVN) (Allegiance HealthcareCorporation).
Methods: Adultpatients (n=40) presenting with Asthma (50%), COPD (10%) and other pulmonarydisorders (40%); receiving pre and post bronchodilator spirometry testing inour Pulmonary Function Lab were included in the study. Each patient receivedboth nebulizers on two separate visits (less than 24 hours apart). Patient receiveda nebulizer treatment with the BAN (n=40) 2.5mg Albuterol (0.5ml) in 0.5cc salinerun to sputter, or the SVN (n=40) 2.5mg Albuterol in 2.5cc saline (3ml unitdose) run to sputter. FVC, FEV1, FEV1% ratio and FEF 25-75% spirometry was conductedusing the Medical Graphics 1085DX pre and 5 minutes post treatment with theBAN and 10 minutes post treatment with the SVN.
Results: The results demonstratedthat FVC, FEV1 and FEF 25-75% for patients using the BAN were substantiallyhigher while FEV1% ratio favored the SVN (Table and Chart ). Importantly, totalnebulization time was reduced from 22 minutes (SVN) to 7 minutes (BAN), andtotal test time was reduced from 30 minutes (SVN) to 15 minutes (BAN).
Conclusion: The administrationof 2.5mg of albuterol with the BAN produced improved results in FVC, FEV1 andFEF 25-75%. Substantially shorter test times delivered by the BAN would allowfor more tests and associated revenue. These data support the thesis that theBAN can reduce costs of care by delivering clinically acceptable outcomes insignificantly less time.